NCT03645824 Myelofibrosis Treated With Pacritinib Before aSCT. (HOVON134MF) Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT03602898 Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation Status WITHDRAWN Phase PHASE2
NCT03566446 CALR Exon 9 Mutant Peptide Vaccine to Patients With CALR-mutant Myeloproliferative Neoplasms Status COMPLETED Phase PHASE1
NCT03560752 CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Allogeneic Transplant Status ACTIVE_NOT_RECRUITING Phase PHASE1
NCT03480360 Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression Status COMPLETED Phase PHASE3
NCT03452774 SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry Status RECRUITING Phase N/A
NCT03438344 Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Reducing CMV Related Complications in Patients With Blood Cancer Undergoing Donor Stem Cell Transplant Status WITHDRAWN Phase PHASE2
NCT03427866 Ruxolitinib Pre-, During- and Post-HSCT for Patients With Primary or Secondary Myelofibrosis. Status COMPLETED Phase PHASE2
NCT03373877 Evaluation of Ruxolitinib in Combination With PU-H71 for Treatment of Myelofibrosis Status TERMINATED Phase PHASE1
NCT03333486 Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer Status TERMINATED Phase PHASE2
NCT03314974 Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders Status RECRUITING Phase PHASE2
NCT03289910 Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT03136185 Bomedemstat (IMG-7289/MK-3543) in Participants With Myelofibrosis (IMG-7289-CTP-102/MK-3543-002) Status COMPLETED Phase PHASE1/PHASE2
NCT03069326 A Clinical Study to Test the Effects of Ruxolitinib And Thalidomide Combination for Patients With Myelofibrosis Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT02934477 Prospective Assessment of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis Status RECRUITING Phase N/A
NCT02916979 Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG Status COMPLETED Phase PHASE1
NCT02910258 Interferon-pegyle α2a Efficiency and Tolerance in Myelofibrosis Status COMPLETED Phase N/A
NCT02877082 Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients Status TERMINATED Phase PHASE2
NCT02807077 PK of Pacritinib in Patients With Mild, Moderate, Severe Renal Impairment and ESRD Compared to Healthy Subjects Status COMPLETED Phase PHASE1